Citations

Clear

1422 citation(s) found for "White, JB".

152 Inflatable Penile Prosthesis Infections: Are We Covered?
White, Lindsay A. , Wen, Lexiaochuan , Ziegelmann, Matt, Trost, L., Köhler, Tobias , Yang, David Y. , Helo, Sevann

Mayo Clinic

The Journal of Sexual Medicine | March 18, 2021 | Volume: 18 | Issue: Supplement_1 | Pages: S82-S82

10.1016/j.jsxm.2021.01.007 Get It

Implications of Atrial Fibrillation on the Mechanisms of Mitral Regurgitation and Response to MitraClip in the COAPT Trial
Gertz, Zachary M. , Herrmann, Howard C. , Lim, D. Scott , Kapadia, Samir , Reed, Grant W. , Puri, Rishi , Krishnaswamy, Amar , Gersh, Bernard J. , Weissman, Neil J., Grayburn, Paul , Redfors, Björn , Zhang, Zixuan , Abraham, William T. , Stone, Gregg W. , Mack, Michael J. , Kapadia, Samir , Herrmann, Howard C , Gersh, Bernard J , Reed, Grant W , Lim, D Scott , Kar, Saibal , Asch, Federico M. , Kosmidou, Ioanna , Lindenfeld, JoAnn

Mayo Clinic

Circulation: Cardiovascular Interventions | March 15, 2021 | Volume: 14 | Issue: 4 | Pages: No page available

10.1161/circinterventions.120.010300 | PMID 33719505 Get It

Background: Atrial fibrillation (AF), mitral regurgitation (MR), and left ventricular (LV) ejection fraction have a complex interplay. We evaluated the role of AF in patients with heart failure and moderate-to-severe or severe secondary MR enrolled in the randomized COAPT trial (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) and its impact on mechanisms and outcomes with the MitraClip. Methods: Patients in the COAPT trial were stratified by the presence (n=327) or absence (n=287) of a history of AF and by assignment to treatment group. Clinical, echocardiographic, and outcome measures were assessed. The primary outcome was the composite rate of death or heart failure hospitalization at 24 months. Results: Patients with history of AF were older and more often male. They had a higher LV ejection fraction, larger left atrial volumes and mitral valve orifice areas, smaller LV volumes, and similar MR severity. Patients with AF compared with those without a history of AF had a higher unadjusted (hazard ratio [HR], 1.32 [95% CI, 1.06–1.64], P =0.01) and adjusted (HR, 1.30 [1.03–1.64], P =0.03) 2-year rate of the primary outcome. Treatment with the MitraClip compared with guideline-directed medical therapy alone reduced death or heart failure hospitalization in both those with (HR, 0.61 [0.46–0.82]) and without (HR, 0.46 [0.33–0.66]) a history of AF ( P int =0.18). Treatment with the MitraClip was associated with a lower risk of stroke in patients with a history of AF (HR, 0.18 [0.04–0.86]) but not in those without a history of AF (HR, 1.64 [0.58–4.62]; P int =0.02). Conclusions: In the COAPT trial, patients with a history of AF had larger left atrial and mitral valve orifice areas with higher LV ejection fraction and smaller LV volumes, suggesting an atrial mechanism contribution to functional MR. Despite the worse prognosis of heart failure patients with a history of AF, MR reduction with the MitraClip still afforded substantial clinical benefits. Treatment with MitraClip was associated with a lower risk of stroke in patients with a history of AF. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01626079.
Abstract P57: Risk Factors for Incidentally Discovered Silent Brain Infarcts and White Matter Disease in a Real World Cohort Identified by Artificial Intelligence
Leung, Lester Y. , Chen, Wansu , Zhou, Yichen, Fu, Sunyang , Zheng, Chengyi , Liu, Hongfang , Kent, David M.

Mayo Clinic

Stroke | March 11, 2021 | Volume: 52 | Issue: Suppl_1 | Pages: No page available

10.1161/str.52.suppl_1.p57 Get It

Introduction: Silent brain infarcts (SBIs) and white matter disease (WMD) are highly prevalent and associated with increased risk of ischemic stroke in patients with traditional stroke risk factors (RFs) in prospective cohort studies. Their frequency and associations with stroke RFs have not been well described in real world populations. Methods: This was a cross-sectional study of patients age ≥ 50 in the Kaiser Permanente-Southern California (KPSC) health system between 2009-2019 with a head CT or MRI for non-stroke indications and no history of ischemic stroke, transient ischemic attack, or dementia. A natural language processing (NLP) algorithm developed at Mayo Clinic and Tufts Medical Center was applied to the KPSC EHR to identify individuals with reported SBIs or WMD. Multivariable Poisson regression with robust error variance was used to estimate risk ratios of demographics, stroke RFs (from the Framingham Stroke Risk Score), and scan modality on the presence of SBIs or WMD. Results: Among 262,875 individuals, the NLP identified 13,154 (5.0%) with SBIs and 78,330 (29.8%) with WMD. Stroke RFs were highly prevalent in this cohort. The majority underwent CTs (74.8%) instead of MRIs as their initial neuroimaging. After adjustment for demographics and RFs, advanced age demonstrated a strong association with increased risk of SBIs and WMD (table). MRI was associated with a reduced risk of reported SBIs (ARR: 0.87, 95% CI 0.83-0.91) and an increased risk of reported WMD (ARR 2.86, 95% CI 2.83-2.90). Despite being prevalent, traditional stroke RFs had weak associations with increased risk of SBIs or increased risk of WMD. Conclusions: Advanced age is strongly associated with incidentally discovered SBIs and WMD on neuroimaging studies obtained in routine care. The development of SBIs and WMD may not be fully attributable to traditional stroke RFs.
Post–Liver Transplant Early Allograft Dysfunction Modifies the Effect of Pre–Liver Transplant Renal Dysfunction on Post–Liver Transplant Survival
Wadei, Hani M. , Mai, Martin L., Hodge, David O. , White, Launia J. , Croome, Kristopher P. , Taner, C. Burcin , Mao, Shennen A. , Jarmi, Tambi , Croome, Kris P , Wadei, Hani M , Keaveny, Andrew P. , Yang, Liu , Mai, Martin L.

Mayo Clinic

Liver Transplantation | March 9, 2021 | Volume: 27 | Issue: 9 | Pages: 1291-1301

10.1002/lt.26047 | PMID 33687745 Get It

Pre–liver transplantation (LT) renal dysfunction is associated with poor post‐LT survival. We studied whether early allograft dysfunction (EAD) modifies this association. Data on 2,856 primary LT recipients who received a transplant between 1998 and 2018 were retrospectively reviewed. Patients who died within the first post‐LT week or received multiorgan transplants and previous LT recipients were excluded. EAD was defined as (1) total bilirubin ≥ 10 mg/dL on postoperative day (POD) 7, (2) international normalized ratio ≥1.6 on POD 7, and/or (3) alanine aminotransferase or aspartate aminotransferase ≥2000 IU/mL in the first postoperative week. Pre‐LT renal dysfunction was defined as serum creatinine >1.5 mg/dL or on renal replacement therapy at LT. Patients were divided into 4 groups according to pre‐LT renal dysfunction and post‐LT EAD development. Recipients who had both pre‐LT renal dysfunction and post‐LT EAD had the worst unadjusted 1‐year, 3‐year, and 5‐year post‐LT patient and graft survival, whereas patients who had neither renal dysfunction nor EAD had the best survival (P < 0.001). After adjusting for multiple factors, the risk of death was significantly higher only in those with both pre‐LT renal dysfunction and post‐LT EAD (adjusted hazard ratio [aHR], 2.19; 95% confidence interval [CI], 1.58‐3.03; P < 0.001), whereas those with renal dysfunction and no EAD had a comparable risk of death to those with normal kidney function at LT (aHR, 1.12; 95% CI, 0.86‐1.45; P = 0.41). Results remained unchanged when pre‐LT renal dysfunction was redefined using different glomerular filtration rate cutoffs. Pre‐LT renal dysfunction negatively impacts post‐LT survival only in patients who develop EAD. Livers at higher risk of post‐LT EAD should be used with caution in recipients with pre‐LT renal dysfunction.
INTACT (S/N1806) phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle-invasive bladder cancer: Safety update on first 73 patients.
Jhavar, Sameer , Hahn, Noah M. , Costello, Brian A. , Tripathi, Abhishek , Gills, Jessie, Jani, Ashesh B. , Bangs, Rick , Plets, Melissa , Feng, Felix Y. , Singh, Parminder Pal , Efstathiou, Jason A. , Tangen, Catherine M. , Delacroix, Scott Edward , Sachdev, Sean , Vogelzang, Nicholas J. , Thompson, Ian M. , Lerner, Seth P.

Mayo Clinic

Journal of Clinical Oncology | March 2, 2021 | Volume: 39 | Issue: 6_suppl | Pages: 428-428

10.1200/jco.2021.39.6_suppl.428 Get It

428 Background: Trimodality therapy (TMT) with maximal TURBT followed by chemoradiation(CRT) is a standard of care for select patients with muscle invasive bladder cancer (MIBC). This trial evaluates the activity of atezolizumab (atezo) in MIBC in combination with TMT. This trial was designed with pre-specified safety analyses of the first 80 patients (40 in each arm). At the time of SWOG fall 2020 DSMC report deadline we had enrolled 84 patients but data on only 73 patients were available. The same data are being submitted to ASCO GU meeting. Methods: This trial is testing atezo every 3 weeks for 6 months given concurrently and adjuvantly with CRT vs. CRT alone in 475 patients with MIBC T2-T4aN0M0 disease. Patients are stratified based on PS; T2 vs T3 or T4; choice of chemotherapy; and radiation field (bladder only vs small pelvis). Patients undergo biopsy 3 months after finishing CRT to assess treatment response. Patients are followed for 5 years for recurrence or survival. This trial was not preceded by a phase I study but was designed with a safety run in of 80 patients. Study team agreed on the study design based on available data from other tumor types and initial experience from investigators running smaller similar trials. It was pre-specified that if we observe more than 25% patients having grade 3-5 colitis or cystitis in the atezo arm or any other toxicity which is deemed clinically significant and related to atezo, the trial investigators and DSMC would consider stopping further enrollment. Results: 36 patients were enrolled on the TMT alone arm and 37 patients on the TMT + atezo arm. No grade 3 or higher colitis was reported in the atezo arm. Only one patient had treatment related grade 3 radiation cystitis which was diagnosed after finishing atezo treatment. No steroids were given. Overall 23 grade 3 or higher toxicity events were reported in the atezo arm vs 11 in non- atezo arm. Most common toxicity was hematological which was considered non-immune related. None of the grade 3 or higher toxicities were considered to be immune related by the treating investigator. Conclusions: There is no evidence of increased immune related grade 3-5 AEs.DSMC has recommended to continue enrollment. Adverse Events with No Entries for Grades 3 to 5 Have Been Suppressed Clinical trial information: NCT03775265 . [Table: see text]
Genetic architectures of proximal and distal colorectal cancer are partly distinct
Huyghe, Jeroen R. , Harrison, Tabitha A. , Figueiredo, Jane C. , Schmit, Stephanie L. , Chen, Sai , Barfield, Richard , Cross, Amanda J. , Diergaarde, Brenda , Duggan, David , Harlid, Sophia , Imaz, Liher , Kang, Hyun Min , Levine, David , Perduca, Vittorio , Perez‐Cornago, Aurora , Slattery, Martha L. , Duijnhoven, Fränzel J.B. van , Guelpen, Bethany Van , Anderson, Kristin E. , Arnau‐Collell, Coral, Banbury, Barbara L. , Berndt, Sonja I. , Bishop, D. Timothy , Boehm, Juergen , Boeing, Heiner , Brenner, Hermann , Buch, Stephan , Burnett‐Hartman, Andrea N. , Carr, Prudence R. , Castells, Antoni , Chang‐Claude, Jenny , Curtis, Keith R. , Chapelle, Albert de la , Easton, Douglas F. , English, Dallas R. , Gala, Manish , Gallinger, Steven , Gauderman, W. James, Goodman, Phyllis J. , Grove, John, Gsur, Andrea , Gunter, Marc J. , Haile, Robert W. , Hampe, Jochen , Hoffmeister, Michael , Hsu, Wan‐Ling, Huang, Wen‐Yi , Joshi, Amit D. , Kühn, Tilman , Küry, Sébastien , Lejbkowicz, Flavio, Li, Li , Lindblom, Annika , Lindor, Noralane M. , Markowitz, Sanford D. , Moreno, Lorena , Murphy, Neil , Nassir, Rami , Offit, Kenneth, Parfrey, Patrick S. , Pearlman, Rachel , Phipps, Amanda I. , Prentice, Ross L. , Qi, Lihong , Rennert, Gad , Rennert, Hedy S., Ríboli, Elio , Schafmayer, Clemens, Seminara, Daniela, Song, Mingyang , Su, Yu‐Ru, Thibodeau, Stephen N. , Thomas, Duncan C. , Trichopoulou, Antonia , Visvanathan, Kala, Vodička, Pavel , Vodičková, Ludmila, Weigl, Korbinian , Weinstein, Stephanie J. , Woods, Michael O. , Wu, Anna H. , Nickerson, Deborah A. , Scacheri, Peter C. , Kundaje, Anshul , Casey, Graham , Gruber, Stephen B. , Hayes, Richard B. , Peters, Ulrike , Visvanathan, Kala , Brenner, Hermann , Buchanan, Daniel D , Chan, Andrew T , Gsur, Andrea , Hampe, Jochen , Hoffmeister, Michael , Huang, Wen-Yi , Jenab, Mazda , Murphy, Neil , Peters, Ulrike , Rennert, Gad , English, Dallas R , Gunter, Marc J , Haile, Robert W , Harrison, Tabitha A , Van Guelpen, Bethany , Visvanathan, Kala , Kury, Sebastien , Bishop, D Timothy , Song, Mingyang , Hayes, Richard B , Perez-Cornago, Aurora , Nassir, Rami , Kundaje, Anshul , Riboli, Elio , Vodicka, Pavel , Diergaarde, Brenda , Lindblom, Annika , Bien, Stephanie A. , Hampel, Heather , Conti, David V. , Qu, Conghui , Lin, Yi , Baron, John A. , Sakoda, Lori C. , Schumacher, Fredrick R. , Toland, Amanda Ewart , Agudo, Antonio , Albanes, Demetrius , Alonso, M. Henar , Arndt, Volker , Bassik, Michael Cory , Bezieau, Stéphane , Boutron‐Ruault, Marie‐Christine , Brezina, Stefanie , Buchanan, Daniel D. , Caan, Bette J. , Campbell, Peter T. , Castellvı́-Bel, Sergi , Chan, Andrew T. , Chanock, Stephen Jacob , Feskens, Edith J. M. , Giles, Graham G. , Grady, William M. , Hopper, John L. , Hudson, Thomas J , Jenab, Mazda , Jenkins, Mark A. , Keku, Temitope O , Kooperberg, Charles , Marchand, Loı̈c Le , Li, Christopher I , Lieb, Wolfgang , Männistö, Satu , Milne, Roger L. , Ogino, Shuji , Panico, Salvatore , Pharoah, Paul D.P. , Platz, Elizabeth A. , Potter, John D. , Raskin, Leon , Schoen, Robert E. , Tangen, Catherine M. , Ulrich, Cornelia M. , Vymetalkova, Veronika Polakova , White, Emily E. , Wolk, Alicja , Abecasis, Gonçalo R. , Hsu, Li , Moreno, Vı́ctor , Newcomb, Polly A.

Mayo Clinic

Gut | February 25, 2021 | Volume: 70 | Issue: 7 | Pages: 1325-1334

10.1136/gutjnl-2020-321534 | PMID 33632709 Get It

Objective An understanding of the etiologic heterogeneity of colorectal cancer (CRC) is critical for improving precision prevention, including individualized screening recommendations and the discovery of novel drug targets and repurposable drug candidates for chemoprevention. Known differences in molecular characteristics and environmental risk factors among tumors arising in different locations of the colorectum suggest partly distinct mechanisms of carcinogenesis. The extent to which the contribution of inherited genetic risk factors for CRC differs by anatomical subsite of the primary tumor has not been examined. Design To identify new anatomical subsite-specific risk loci, we performed genome-wide association study (GWAS) meta-analyses including data of 48 214 CRC cases and 64 159 controls of European ancestry. We characterised effect heterogeneity at CRC risk loci using multinomial modelling. Results We identified 13 loci that reached genome-wide significance (p<5×10 −8 ) and that were not reported by previous GWASs for overall CRC risk. Multiple lines of evidence support candidate genes at several of these loci. We detected substantial heterogeneity between anatomical subsites. Just over half (61) of 109 known and new risk variants showed no evidence for heterogeneity. In contrast, 22 variants showed association with distal CRC (including rectal cancer), but no evidence for association or an attenuated association with proximal CRC. For two loci, there was strong evidence for effects confined to proximal colon cancer. Conclusion Genetic architectures of proximal and distal CRC are partly distinct. Studies of risk factors and mechanisms of carcinogenesis, and precision prevention strategies should take into consideration the anatomical subsite of the tumour.
White Paper on Ophthalmic Imaging for Choroidal Nevus Identification and Transformation into Melanoma
Lally, Sara E. , Pellegrini, Marco , Kaliki, Swathi , Gündüz, Kaan , Fung, Adrian T. , Duker, Jay S. , Selig, Sara , Yaghy, Antonio , Ferenczy, S , Eydelman, Malvina, Blumenkranz, Mark S. , Shields, Carol L. , Dalvin, Lauren A. , Sagoo, Mandeep S. , Furuta, Minoru , Mruthyunjaya, Prithvi

Mayo Clinic

Translational Vision Science & Technology | February 20, 2021 | Volume: 10 | Issue: 2 | Pages: 24

10.1167/tvst.10.2.24 | PMID 34003909 Get It

Assessment of kidney function: clinical indications for measured GFR
Ebert, Natalie , Bevc, Sebastjan , Bökenkamp, Arend , Gaillard, F. , Mariat, Christophe , Pálsson, Runólfur , Londen, Marco van , Schäeffner, Elke , Gaillard, Francois , Palsson, Runolfur , Schaeffner, Elke , Bökenkamp, Arend , van Londen, Marco , Ebert, Natalie , Hornum, Mads , Jager, Kitty J. , Eriksen, Björn O. , Rule, Andrew D. , White, Christine A.

Mayo Clinic

Clinical Kidney Journal | February 18, 2021 | Volume: 14 | Issue: 8 | Pages: 1861-1870

10.1093/ckj/sfab042 | PMID 34345408 Get It

Abstract In the vast majority of cases, glomerular filtration rate (GFR) is estimated using serum creatinine, which is highly influenced by age, sex, muscle mass, body composition, severe chronic illness and many other factors. This often leads to misclassification of patients or potentially puts patients at risk for inappropriate clinical decisions. Possible solutions are the use of cystatin C as an alternative endogenous marker or performing direct measurement of GFR using an exogenous marker such as iohexol. The purpose of this review is to highlight clinical scenarios and conditions such as extreme body composition, Black race, disagreement between creatinine- and cystatin C–based estimated GFR (eGFR), drug dosing, liver cirrhosis, advanced chronic kidney disease and the transition to kidney replacement therapy, non-kidney solid organ transplant recipients and living kidney donors where creatinine-based GFR estimation may be invalid. In contrast to the majority of literature on measured GFR (mGFR), this review does not include aspects of mGFR for research or public health settings but aims to reach practicing clinicians and raise their understanding of the substantial limitations of creatinine. While including cystatin C as a renal biomarker in GFR estimating equations has been shown to increase the accuracy of the GFR estimate, there are also limitations to eGFR based on cystatin C alone or the combination of creatinine and cystatin C in the clinical scenarios described above that can be overcome by measuring GFR with an exogenous marker. We acknowledge that mGFR is not readily available in many centres but hope that this review will highlight and promote the expansion of kidney function diagnostics using standardized mGFR procedures as an important milestone towards more accurate and personalized medicine.
Joy in the Workplace: A Scoping Review of Positive Emotion and Electroencephalogram
Yusuf, Yaqoub, Boutté, Jodi, Lloyd, Asante’, Fortune, Emma , Blocker, Renaldo C.

Mayo Clinic

Proceedings of the Human Factors and Ergonomics Society Annual Meeting | February 13, 2021 | Volume: 64 | Issue: 1 | Pages: 1493-1497

10.1177/1071181320641357 Get It

A workplace that is a conduit for positive emotions can be important to employees retention and can contribute optimal levels of productivity. Validated tools for examining emotions are primarily subjective and retrospective in nature. Recent advances in technology have led to more novel and passive ways of measuring emotions. Wearable sensors, such as electroencephalogram (EEG), are being explored to assess cognitive and physical burdens objectively and in real-time. Therefore, there exists a need to investigate and validate the use of EEG to examine emotions objectively and in real-time. In this paper, we conducted a scoping review of EEG to measure positive emotions and/or indicators of joy in the workplace. Our review results in 22 articles that employ EEG to study joy in occupational settings. Three major themes identified in the analysis include (1) EEG for symptoms detection and outcomes, (2) Populations studied using EEG, and (3) EEG electrode systems.
Aspiration Thrombectomy: 2-Dimensional Operative Video
Turner, Raymond D , Turk, Aquilla S , Bain, Mark, Bendock, Bernard, Binning, Mandy J., Boulos, Alan S. , Crowley, Webster, Fessler, Richard D., Guterman, Lee R., Hoit, Daniel , Hopkins, L. Nelson , Howington, Jay U., James, Robert F. , Jankowitz, Brian T. , Kan, Peter , Khalessi, Alex A, Kim, Louis J. , Langer, David J. , Lanzino, Giuseppe, Levitt, Michael , Levy, Elad, Mack, William J. , Mericle, Robert A., Ogilvy, Chris, Replogle, Robert, Riina, Howard A. , Saugaveau, Eric, Schirmer, Clemens M. , Spiotta, Alex, Sultan, Ali, Veznedaroglu, Erol, Welch, Babu G. , White, Jonathan, Schirmer, Clemens M , Chaudry, Imran , Vargas, Jan , Arthur, Adam Stephen , Grande, Andrew Walker , Hanel, Ricardó A. , Kim, Louis J. , Lanzino, Giuseppe , Levitt, Michael, Levy, E, Lopes, Demetrius K. , Mocco, J , Pandey, Aditya S , Ringer, Andrew J. , Rodriguez, Rafael, Siddiqui, Adnan H. , Tawk, Rabih G. , Thomas, Ajith J , White, Jonathan A.

Mayo Clinic

Operative Neurosurgery | February 12, 2021 | Volume: 20 | Issue: 4 | Pages: E286-E287

10.1093/ons/opaa471 | PMID 33575807 Get It

Abstract Acute ischemic stroke is one of the leading causes of disability and mortality worldwide. There have been significant improvements to the treatment of acute ischemic stroke over the past 5 yr, specifically related to strokes caused by large vessel occlusions. Stent retrievers with and without local aspiration and direct aspiration alone have all been demonstrated as viable treatment options for this patient population. This case represents the surgical technique for direct aspiration for the treatment of large vessel occlusion. A 76-yr-old man presented with right-sided weakness and aphasia. His last known normal was 5 h ago. His NIHSS (National Institutes of Health Stroke Scale) was 18. The noncontrast computed tomography (CT) did not show a significant infarct burden and ASPECTS (Alberta Stroke Program Early CT Score) of 9. CT angiogram demonstrated a left M1 occlusion. The patient was not a candidate for tissue plasminogen activator (tPA) because of time to presentation; however, the patient was deemed to be a candidate for emergent thrombectomy. Consent was obtained per institutional guidelines for the emergent procedure and the video recording. The video demonstrates a direct aspiration thrombectomy technique for the treatment of stroke. The patient successfully underwent direct aspiration thrombectomy with a TICI 3 (thrombolysis in cerebral infarction) recanalization.